Dapoxetina Cloridrato – Video

29-11-2011 13:28 Dapoxetina Cloridrato - link to online store ultrarx.org Priligy (Dapoxetine) Dapoxetine also known as Priligy® is a new drug that has gained most of the people's interest and it is used as a treatment for premature ejaculation. The marvelous quality of Dapoxetine - Priligy dapoxetina cloridrato farmaco dapoxetina cloridrato eiaculazione precoce dapoxetina cloridrato priligy dapoxetina cloridrato categoria dapoxetina cloridrato priligy generico dapoxetina cloridrato

Read the rest here:
Dapoxetina Cloridrato - Video

Buy HGH online – Video

05-12-2011 08:40 Buy HGH online - link to online store rxdrughost.com Growth Hormone Certified Natural HGH is a revolutionary new Human Growth Hormone supplement. Each bottle contains 60 capsules, filled with only the finest all-natural pharmaceutical grade ingredients. The first class quality of Growth...

See the original post here:
Buy HGH online - Video

Lexapro and marijuana – Video

19-12-2011 12:36 Link to online store pillsrx24.com Lexapro and marijuana Like with all prescription drugs, it is very important that you follow the instructions that were given to you by your doctor when they prescribed Lexapro to you. Lexapro 20mg gastrointestinal tract (gs tr - nt st -nl). The digestive tract, especially of a human. ThesaurusLegend: Synonyms Related Words Antonyms. He walks straight up, reaches into my box of books, and grabs one out, beginning to unwrap it himself. Scott W shares his strategy for evaluating and learning new technologies and how to successfully manage remote development teams. Exact Eye Care Inc. a dynamic full service optical company, optometry services, eye glasses, reading glasses, contact lenses. lexapro and marijuana

View post:
Lexapro and marijuana - Video

Modapro Buy – Video

30-12-2011 09:31 Modapro Buy - link to online store GenuineTabs.com Modafinil (Modalert) 100 mg / 200 mg Modalert is currently approved to treat excessive sleepiness in adults with narcolepsy, obstructive sleep apnea, and shift work sleep disorder. The admirable quality of smart drugs buy modapro side...

See original here:
Modapro Buy - Video

Dr. David Gorski – (So-Called) Complimentary and Alternative Medicine | For Good Reason – Video

03-02-2012 16:16 Dr. Gorski defines complementary, alternative and integrative medicine and contrasts it with science-based medicine. He talks about whether its acceptance is growing. He debates to what extent massage therapy and aromatherapy are examples of CAM. He reveals whether he likes to refer to CAM as (S)CAM, and how helpful such an acronym is. He explores to what extent traditional medicine and herbal medicine are science-based, resulting in aspirin, digitalis, and various chemotherapy drugs, and why they should not properly be considered CAM. He describes the health freedom movement, and what social criticism fuels it. He talks about the ways that adopting CAM approaches harm patients, including leading to patents to forgo other, more effective treatments; paternalistic deception of the patient through knowing use of placebo. He explores the moral values that motivate skeptical activism. And he talks about why more medical doctors are not skeptic activists.

Go here to see the original:
Dr. David Gorski - (So-Called) Complimentary and Alternative Medicine | For Good Reason - Video

The Psychology of Meditative Thinking: Wellness in Integrative Medicine – Video

09-02-2012 08:16 Learn how mindfulness meditation-based interventions are impacting healthcare and society. James Mitchell discusses both the philosophical and practical aspects, as well as how to cultivate and move towards a psychology of meditative thinking. This presentation will include an experiential session and is designed for professionals, mindfulness-based enthusiasts or for those interested in mind/body training and healing. Series: "Integrative Medicine Today" [2/2012] [Health and Medicine] [Show ID: 23407]

More here:
The Psychology of Meditative Thinking: Wellness in Integrative Medicine - Video

Bunker Mentality: Harman flirts with immortality

Sat, 03 Mar 02:41:00 2012

Golf tends to toss up great out-of-nowhere stories about once a month, and March's version arrived on the second day.

Brian Harman, the second alternate coming into this week's Honda Classic, stood on the tee at 18 with a chance at achieving golf nirvana: the fabled sub-60 round.

Alas, it wasn't to be; he needed an eagle to pull off a 59, and "only" managed a par. Still, Harman's 61, a 9-under round, was good enough to set the course record at PGA National by three strokes. He sat just two strokes off the lead with players still on the course Friday afternoon.

"I walked off 16 and I was like, man, if I birdie these last two holes, I'm going to shoot 59," he said afterward. "I hit a great drive on 18 and had a chance I mean, I had a chance." His approach on 18 found the bunker, he wasn't able to get up and down, and he missed a 5-footer that would have left him at 60. Still, not a bad afternoon's work.

Making Harman's achievement far more impressive is the difficulty of the PGA National course. "This is probably one of the hardest golf courses we play all year, and just to have a chance to do something special like that is really humbling and it's really cool," he said. "I saw where Davis [Love III] had shot 64 yesterday ... I'm like, How did he shoot 64 out here? This place is so hard."

He got some key advice from a former U.S. Open champ that may well have helped. "I really tried to slow myself down," he said. "Exchanged some text messages with Lucas Glover last night. He's been a really good friend to me, and every time that I've needed any help, he's always given me some advice. I asked him, I said, 'Man, how do you get out there and take your time?' He goes, 'Well, try to walk a little slower.' I did that today."

While we hope for the best for Mr. Harman in his future endeavours, we can say with authority that if this leads to even slower play on the course? Apocalypse.

Excerpt from:
Bunker Mentality: Harman flirts with immortality

Schuster: Team Chemistry Vital To Success

Adam Dunn and Paul Konerko (Photo Credit: Getty Images, By: David Banks)

By David Schuster-

MESA, Ariz. (CBS) Chemistry and camaraderie are extremely important to winning in baseball, if you believe most players.

Heres a sample from both ends of town on the subject.

Ive mentioned for a long time its ultra-important in baseball, and especially so at Wrigley Field said Cubs pitcher, Jeff Samardzija. Its a small clubhouse and were right on top of each other and you need to have a close team and need to understand each other. There are going to be some run ins, but as long as you have that foundation and have everybody pulling for each other, you can brush those things aside and move on.

Meanwhile, on the other side of town, White Sox pitcher John Danks couldnt agree more.

You have to like coming to the ball park, so I think its critical, he said. You have to enjoy coming to work and if you dont like your teammate or have a problem with some guys, youre not going to enjoy it. Fortunately, we have a great group of guys and everyone gets along.

Danks knows if ever there is a problem, then the team captain Paul Konerko will intervene.

Paulie is a guy we lean on, Danks said. Hes the captain for a reason. He goes about it the right way and has the respect of everybody.

Gordon Beckham has only been in the majors for a short period of time, but he also knows the value of having a tight clubhouse.

View original post here:
Schuster: Team Chemistry Vital To Success

BIO Announces Expansion of Alliance Development Activities

WASHINGTON--(BUSINESS WIRE)--

The Biotechnology Industry Organization (BIO) announced today that it has integrated its alliance development activities into one department as a means of expanding engagement opportunities with external groups that share a commitment to unleashing biotechnologys capability to benefit patients and consumers.

Gillian Mullins has been promoted to lead this enhanced effort as the Managing Director, Alliance Development. Mullins will oversee BIO's external relationships with allied organizations, including: patient advocacy organizations, physician and payer groups, universities, venture capital organizations and the state-based bioscience trade groups that comprise the Council of State Bioscience Association (CSBA).

"BIO's Alliance Development activities are a central element of our organization's directive to promote responsible growth of the bioscience industry while improving understanding of policy issues critical to the industry and patients we serve, said Fritz Bittenbender, BIO's vice president of Alliance Development and State Government Relations. "Through these partnerships we support an industry that is researching and developing new cures and treatments for debilitating diseases including cancer, Multiple Sclerosis and HIV/AIDS and by providing cutting-edge technologies to improve crop yields, and discover cleaner forms of home-grown energy."

"BIO's commitment to partnering with and supporting the initiatives of other similarly aligned trade organizations has played an understated yet invaluable role in advancing the bioscience industry's legislative and regulatory interests," said Chris Rivera, president of the Washington Biotechnology & Biomedical Association and chairman of the CSBA. "In particular, BIO's stewardship of the CSBA has brought together 51 life sciences trade organizations with divergent interests from across the U.S. under the unified banner of promoting public understanding and advocacy for sound public policy that benefits us all."

For more information on BIO, please visit our website at http://www.bio.org.

Upcoming BIO Events

World Congress on Industrial Biotechnology & Bioprocessing April 29-May 2, 2012 Orlando, FL

2012 BIO International Convention June 18-21, 2012 Boston, MA

BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the worlds largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIO produces BIOtechNOW, an online portal and monthly newsletter chronicling innovations transforming our world. Subscribe to BIOtechNOW.

View post:
BIO Announces Expansion of Alliance Development Activities

Teleconference for Reporters – Chairwoman Stabenow’s New Legislation Supports Bio-Manufacturing

Biotechnology Industry Organization:

WHAT:

Sen. Debbie Stabenow (D-Mich.), chairwoman of the Senate Agriculture Committee, recently introduced the Grow It Here, Make It Here initiative, which will allow more renewable chemical, biobased product and bio-manufacturing companies to existing USDA initiatives. The Biotechnology Industry Organization (BIO) and its member companies will discuss the economic impact and job creation potential of Sen. Stabenows legislation.

WHO:

Chris Adamo, Staff Director, Senate Agriculture Committee;

WHEN:

RSVP:

About BIO

BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the worlds largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIO produces BIOtech NOW, an online portal and monthly newsletter chronicling innovations transforming our world. Subscribe to BIOtech NOW.

Upcoming BIO Events

Original post:
Teleconference for Reporters – Chairwoman Stabenow’s New Legislation Supports Bio-Manufacturing

ImmunoCellular Therapeutics and Human Genome Science Make Headway in Booming Biotechnology Industry

NEW YORK, NY--(Marketwire -03/02/12)- Biotechnology shares have been on impressive run of late. Led by the growing popularity in early stage biotechnology companies, the iShares Nasdaq Biotechnology Index Fund is up roughly 20 percent over the last three months. A recent survey from BIO Industry Analysis finds that investors are more focused on early stage companies than later. "And, this sentiment is also borne out by the increase in percentage of investors who indicate that they are willing to invest in small market cap biotechs," Alan Eisenberg, executive vice president of emerging companies and business development, explained. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on ImmunoCellular Therapeutics Ltd. (OTC.BB: IMUC.OB - News) and Human Genome Sciences, Inc. (NASDAQ: HGSI - News). Access to the full company reports can be found at:

http://www.paragonreport.com/IMUC

http://www.paragonreport.com/HGSI

Biotech firms continue to negotiate a more challenging regulation process. The FDA Amendments Act of 2007 forced regulators to increase standards for approvals of new drugs, introducing mandatory risk evaluation and mitigation strategies. According to a Pharmaceuticals & Biotechnology report from IMAP, several pharmaceutical firms have altered their drug portfolios from primary care driven blockbusters towards specialties such as oncology, immunology and inflammation, where the medical need is "so high that prices are more easily accepted by the regulators."

The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at http://www.paragonreport.com and get exclusive access to our numerous stock reports and industry newsletters.

ImmunoCellular Therapeutics, Ltd., a development stage company, focuses on developing and commercializing therapeutics to treat cancer using the immune system. Earlier this week the company entered into an agreement with The Johns Hopkins University (JHU) under which JHU has granted the Company an exclusive, worldwide license to intellectual property surrounding the tumor-associated antigen mesothelin, which is highly expressed in pancreatic cancer, ovarian cancer and mesothelioma.

Human Genome Sciences, Inc. operates as a biopharmaceutical company. Its principal products in development include BENLYSTA for systemic lupus erythematosus; and raxibacumab for inhalation anthrax. Earlier this week the company reported $25.7 million in sales of Benlysta for the period that ended Dec. 31 -- $29.1 million, excluding adjustments. U.S. regulators approved the drug in March, and European Union regulators did the same in July.

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.paragonreport.com/disclaimer

Original post:
ImmunoCellular Therapeutics and Human Genome Science Make Headway in Booming Biotechnology Industry

Student Innovation at Rensselaer Polytechnic Institute Seeks to Mend Previously Untreatable Tissue Injuries

Christopher Rivet Is One of Three Finalists for the $30,000 2012 Lemelson-MIT Rensselaer Student Prize

Newswise Troy, N.Y. Christopher Rivet has successfully married two powerful bioengineering technologies to develop a new method for delivering drugs directly to an injury site and jumpstarting the process of tissue regeneration. His innovation could be an important new tool in preventing paralysis resulting from spinal cord trauma, cancer, diabetes, or a host of other diseases.

Rivet, a doctoral student in the Department of Biomedical Engineering at Rensselaer Polytechnic Institute, is one of three finalists for the 2012 $30,000 Lemelson-MIT Rensselaer Student Prize. A public ceremony announcing this years winner will be held at 6:45 p.m. on Wednesday, March 7, in the auditorium of the Rensselaer Center for Biotechnology and Interdisciplinary Studies. For more information on the ceremony visit: http://www.eng.rpi.edu/lemelson

Rivets project is titled A Hydrogel and Electrospun Fiber Composite Material, and his faculty adviser is Ryan Gilbert, assistant professor of biomedical engineering at Rensselaer.

Sadly, there is no shortage of situations that lead to a loss of functioning tissue and, in turn, paralysis. These circumstances can range from the surgical removal of a tumor, to untreated bedsores, to a spinal cord injury stemming from a gunshot wound or traffic accident. All of these situations require action first to stop the progression of the injury, and secondly to restore function to the damaged tissue. However, there is currently no treatment, short of receiving a transplant from a donor, to simultaneously pursue both goals and more effectively mitigate the onset of paralysis.

Rivets patent-pending invention pairs electrospun fibers with hydrogels to help solve this important societal need. He has developed a new way to disperse nanoscopic electrospun fibers, which can prompt and guide tissue regeneration, within injectable, drug-infused hydrogels. The result is an advanced biomaterial that can mimic and serve as a temporary replacement for living tissue.

For example, potential target could be a patient who had a large bone tumor removed, leaving behind a hole that is too large for the body to recover from on its own. The surgeon may elect to use a hydrogel. Injected as a liquid, the hydrogel would firm up and fill in the unique shape of the void. Hydrogels can be treated with different drugs to help stop progression of the injury, and the gels can be tuned to match the mechanical properties of the tissue their replacing. However, hydrogels cannot carry the appropriate chemical cues to guide regenerative nerve cells into and out of the injury site. This means hydrogels alone are not a winning strategy for combating the onset of paralysis.

Rivet has incorporated electrospun fibers, which are spun from polymer and can carry guidance cues and promote functional recovery, into hydrogels. The end result is a complex system that can deliver multiple drugs as well as the necessary guidance cues to coax nerve cells through the injury site and kick start the process of regeneration. As the patients body tissue regenerates, the hydrogels and electrospun fibers simply dissolve harmlessly. Rivets system is also highly adaptable, as different electrospun fibers can be matched with various hydrogels to achieve specific goals.

When not in the lab or classroom, Rivet enjoys spending time outdoors. If hes not skiing, cycling, or hiking, you can probably find him on the lake fishing. At home in Grand Blanc, Mich., Rivets family and friends are rooting for him to win the $30,000 Lemelson-MIT Rensselaer Student Prize. His mother is a high school math and science teacher and his father works for the United Auto Workers labor union. Rivets older sister is a laboratory manager at Kettering University.

Rivet was curious and creative as a young student, and he strives to foster those virtues in others. He is an active mentor in local elementary schools and high schools, sparking the interest of students and encouraging them to seek out opportunities to study and work in the fields of science, technology, engineering, or mathematics. He also mentors several undergraduate students at Rensselaer.

See original here:
Student Innovation at Rensselaer Polytechnic Institute Seeks to Mend Previously Untreatable Tissue Injuries

Anatomy of a Winnipeg Jets Blowout: Fan's Take

A close game was expected between the Winnipeg Jets and the Southeast division-leading Florida Panthers on Thursday, March 1 at the MTS Centre. Let's just say the game didn't go according to plan, as the Jets routed the Panthers, 7-0. Here's a timeline of the evening's stunning events.

Fans cheer the Jets at the MTS Centre. Wikimedia Commons

7:32 p.m. Winnipeg comes into the game four points behind the Panthers in the Southeast and one point out of eighth place in the Eastern Conference. The home crowd senses the importance of the game, as the Jets take the ice to a vociferous, standing ovation. It'll get louder before the game is over.

7:43 p.m. Evander Kane steals the puck in Florida's zone, skates in alone and beats Panthers goaltender Jose Theodore at 4:01 of the first period for the first goal of the game. In the process, Kane extends his career-high point streak to eight games.

7:46 p.m. Jim Slater buries a rebound at 6:03 of the first to make it 2-0. Mark Stuart and Chris Thorburn draw assists on Slater's ninth goal of the season and first in 19 games. So much for the Panthers taking the crowd out of the game. Only a few minutes into the action, the MTS Centre is rocking.

8:13 p.m. End of the first period. Winnipeg leads the Panthers in both shots and hits at 13-7 and 15-7, respectively. The Jets are showing no ill effects from Monday's 5-3 loss to the Edmonton Oilers in which they allowed four unanswered goals in the third period.

9:01 p.m. End of the second period. The Jets still lead 2-0, but Florida controlled play for much of the middle frame, outshooting Winnipeg, 17-8. The Jets record this season when leading after three periods is 23-3-1. Conversely, Florida is 3-17-2 when trailing after three.

9:21 p.m. Kyle Wellwood tips home Stuart's blast from the top of the circle at 1:49 of the third period to make it 3-0. Kane draws the secondary assist for his second point of the game.

9:25 p.m. The Panthers turn over the puck in Winnipeg's zone, sparking an unheard of 5-on-1 rush the other way. Blake Wheeler ultimately feeds Bryan Little, who fires into an empty net for his 19th goal of the season to make it 4-0. Scott Clemmensen replaces Theodore to the delight of the MTSC crowd.

9:33 p.m. Nik Antropov bangs home a loose puck in front of the cage on the power play for his 10th goal of the seasonthe Jets lead, 5-0. Winnipeg entered the game with the top-ranked home power play in the National Hockey League. The Jets went 1-for-3 on the man advantage.

Originally posted here:
Anatomy of a Winnipeg Jets Blowout: Fan's Take

Cannabis Science Issues Potential Revenues And Market Data for the New Cannabis Science Brand OTC Products

DENVER--(BUSINESS WIRE)--Cannabis Science, Inc. (OTCBB:CBIS.OB - News) a pioneering U.S. biotech company developing pharmaceutical cannabis and hemp products, issues market data for the four Cannabis Science brand products for the newest over-the-counter line to be released.

The Global Anti-Aging Products Market to reach $291.9 Billion by 2015, and the U. S. Market for Anti-Aging Products for Appearance Enhancement is expected to be more than US$5.0 billion by 2015. The global cosmeceuticals market is US$ 27.2 Billionin 2010 according to a new report by Global Industry Analysts. The US market for skin irritation creams and sunscreen is $6.5 billion. US demand for cosmeceutical products is expected to increase 5.8 percent annually through 2015. The Global Lip Care Products Market is expected to reach $1.7 Billion by 2015. (reportlinker.com NEW YORK,Jan. 11, 2012/PRNewswire)

Cannabis Science is among the leading experts specializing in developing all natural organic bio healing hemp health, beauty and cosmetics products. Our philosophy is to bring the best products possible to the entire world, to help improve and promote a healthier natural way of life. Superior products are born from scientific data and research and we have come to a new understanding in the keys to our product development.

Dr. Moe Afaneh, Cannabis Science COO, explained, We believe our sunscreen and protectant is far superior to others, because we have invested time into understanding what occurs in the body and on the skin, and targeting the cascade of events that occurs when people get sunburned. We have meticulously targeted key components that lead to the sunburn and have created our elite formulation so that one instantly feels the skin begin to cool, the pain begins to dissipate and the healing process has begun. We have created our own cascade of healing properties using the finest natural ingredients to mimic our bodys natural pathway when responding to a skin burn.

Dr Afaneh added, Another of our topical skin care products helps provide relief to various skin conditions such as eczema and other recurring skin irritations. We have studied various populations and age groups that suffer from acute and chronic skin irritations. These symptoms varied from raised dry patches of skin, red blotches, hardened patches, mostly appearing in areas of the arms and legs, as well as areas of the body that tended to constantly rub against clothing or other surfaces. Our specialized formulation was designed based on understanding the patients expectations from over-the-counter skin care products. By understanding patients needs, we created our all natural unique formulation to help improve their quality of life on daily basis. It is designed to help stop the itching and pain, first and foremost, and then begins to lock moisture in and around the area, and then our natural blend of ingredients begins to help the body heal the skin and reduce the irritation.

Dr. Afaneh concludes with, Our anti-aging skin serum, specifically formulated for women, helps rejuvenate and soften the skin. The Cannabis Science serum uses only natural ingredients, including hemp oil extract and many other natural oils and ingredients. Our serum leaves the skin looking radiant, energized, softer, healthier, and full of life. Our all-natural lip balm that contains hemp oil extract and our unique blend of ingredients and is unique in that it has natural ingredients that help protect against bacteria and fungus. It also has SPF to protect against the harmful effects of the sun, and is infused with antioxidants and many other natural extracts to soften the lips and lock the moisture in.

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.

The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements

See more here:
Cannabis Science Issues Potential Revenues And Market Data for the New Cannabis Science Brand OTC Products

'Living fossil' trees in DNA studies

Published: March. 2, 2012 at 5:49 PM

BRISBANE, Australia, March 2 (UPI) -- Scientists say they are using cutting-edge DNA sequencing technology to protect living fossil trees in Fiji from the impact of climate change.

Peter Prentis from the Queensland University of Technology in Brisbane, Australia, said the findings would enable researchers to understand how biological diversity is generated.

"Fiji is a hot spot for biodiversity," he said. "Most of the species that occur in Fiji aren't found anywhere else in the world."

Prentis is using DNA sequencing to study the genes of living fossil tree species, all either endangered or vulnerable, a university release said Friday.

Living fossil is a term for any living species appearing to be the same as a species otherwise only known from fossils and which has no close living relatives.

"With climate change these species are going to have to respond to increasingly changing environmental conditions and an increase in extreme events, such as cyclones," Prentis said.

"We don't know if these living fossil trees have the potential to adjust to these future environments."

The DNA research would compare the vulnerable or endangered tree species with ones more commonly found in Fiji, he said.

"We'll analyze each of the species pairs to find genes that have been important in the process of becoming unique. We're interested in how these rare species evolve," he said.

See original here:
'Living fossil' trees in DNA studies

Posted in DNA

UCLA researchers stop Parkinson’s progression in animal tests

Raleigh Neurology/Flickr

Flexibility testing at a Parkinson's clinic.

A possible breakthrough has happened in the treatment of Parkinsons disease. UCLA researchers have found a way to stop the progression of the disease in animal tests.

Parkinsons is a disease that strikes the nervous system, affecting ones movements. So far, there are no treatments to stop its progression. Medical professionals aren't even sure what actually causes it.

But researchers do believe one particular protein in the brain plays a role. Its found in clumps in all Parkinson's patients.

Researchers at UCLA have created a compound that prevents the protein from clumping. They call it a "molecular tweezer." In live animal tests, the compound binds to that protein, prevents it from aggregating and even breaks up existing clumps.

Most importantly, the compound did this without appearing to harm normal brain cells.

The study was done with transparent zebrafish. Now the findings are being applied to mice. Human trials, they hope, will be next.

Continue reading here:
UCLA researchers stop Parkinson's progression in animal tests

UCLA researchers stop Parkinson's progression in animal tests

Raleigh Neurology/Flickr

Flexibility testing at a Parkinson's clinic.

A possible breakthrough has happened in the treatment of Parkinsons disease. UCLA researchers have found a way to stop the progression of the disease in animal tests.

Parkinsons is a disease that strikes the nervous system, affecting ones movements. So far, there are no treatments to stop its progression. Medical professionals aren't even sure what actually causes it.

But researchers do believe one particular protein in the brain plays a role. Its found in clumps in all Parkinson's patients.

Researchers at UCLA have created a compound that prevents the protein from clumping. They call it a "molecular tweezer." In live animal tests, the compound binds to that protein, prevents it from aggregating and even breaks up existing clumps.

Most importantly, the compound did this without appearing to harm normal brain cells.

The study was done with transparent zebrafish. Now the findings are being applied to mice. Human trials, they hope, will be next.

Continue reading here:
UCLA researchers stop Parkinson's progression in animal tests

Parkinson's patients to swamp homes

Australia's nursing homes will be swamped by a tidal wave of Parkinson's sufferers unless governments act now, an expert warns.

A Sydney-based Parkinson's disease expert says rates are expected to jump 80 per cent over the next 20 years because of Australia's aging population.

Currently 64,000 people have the progressive brain disease that causes uncontrollable tremors, loss of movement and bowel and bladder problems.

Associate Professor Simon Lewis from the University of Sydney is expected to present new research on the benefits of community-based Parkinson's nurses at a nursing conference on the Gold Coast on Friday.

Professor Lewis says Australia must adopt the UK approach of employing the specialist nurses or pay the price in nursing home care costs.

'You have to have a way of addressing this tidal wave of patients who are coming over the next 20 years,' he told AAP.

His research indicates that access to specialist nurses in the community can stave off the need for nursing home accommodation.

He compared the health of Parkinson's sufferers and their carers in Shoalhaven, NSW, before and six months after they were placed in the care of a specialist nurse.

'Very clearly what we saw is that during the time they had been seeing the nurse the patient's health had improved,' he said.

'More importantly, the carers themselves reported that their own health had improved.'

Here is the original post:
Parkinson's patients to swamp homes